283 related articles for article (PubMed ID: 14707287)
21. The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents.
Gillet R; Grimber G; Bennoun M; Caron de Fromentel C; Briand P; Joulin V
Oncogene; 2000 Jul; 19(31):3498-507. PubMed ID: 10918608
[TBL] [Abstract][Full Text] [Related]
22. Synergistic suppression of prostatic cancer cells by coexpression of both murine double minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo.
Ji K; Wang B; Shao YT; Zhang L; Liu YN; Shao C; Li XJ; Li X; Hu JD; Zhao XJ; Xu DQ; Li Y; Cai L
J Pharmacol Exp Ther; 2011 Jul; 338(1):173-83. PubMed ID: 21444629
[TBL] [Abstract][Full Text] [Related]
23. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression.
Meng RD; Shih H; Prabhu NS; George DL; el-Deiry WS
Clin Cancer Res; 1998 Jan; 4(1):251-9. PubMed ID: 9516979
[TBL] [Abstract][Full Text] [Related]
24. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo.
Reinke V; Lozano G
Oncogene; 1997 Sep; 15(13):1527-34. PubMed ID: 9380404
[TBL] [Abstract][Full Text] [Related]
25. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
[TBL] [Abstract][Full Text] [Related]
26. Bax accelerates tumorigenesis in p53-deficient mice.
Knudson CM; Johnson GM; Lin Y; Korsmeyer SJ
Cancer Res; 2001 Jan; 61(2):659-65. PubMed ID: 11212265
[TBL] [Abstract][Full Text] [Related]
27. Aberrant p21 regulation in radioresistant primary glioblastoma multiforme cells bearing wild-type p53.
Kraus A; Gross MW; Knuechel R; Münkel K; Neff F; Schlegel J
J Neurosurg; 2000 Nov; 93(5):863-72. PubMed ID: 11059670
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.
Lang FF; Yung WK; Raju U; Libunao F; Terry NH; Tofilon PJ
J Neurosurg; 1998 Jul; 89(1):125-32. PubMed ID: 9647183
[TBL] [Abstract][Full Text] [Related]
29. Combined radiation and p53 gene therapy of malignant glioma cells.
Badie B; Goh CS; Klaver J; Herweijer H; Boothman DA
Cancer Gene Ther; 1999; 6(2):155-62. PubMed ID: 10195882
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
31. The potential tumor suppressor p73 differentially regulates cellular p53 target genes.
Zhu J; Jiang J; Zhou W; Chen X
Cancer Res; 1998 Nov; 58(22):5061-5. PubMed ID: 9823311
[TBL] [Abstract][Full Text] [Related]
32. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.
Osman I; Drobnjak M; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 Aug; 5(8):2082-8. PubMed ID: 10473090
[TBL] [Abstract][Full Text] [Related]
33. Induction of apoptosis by p53, bax, bcl-2, and p21 expressed in colorectal cancer.
Katsumata K; Sumi T; Tomioka H; Aoki T; Koyanagi Y
Int J Clin Oncol; 2003 Dec; 8(6):352-6. PubMed ID: 14663636
[TBL] [Abstract][Full Text] [Related]
34. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.
Shukla S; Maclennan GT; Marengo SR; Resnick MI; Gupta S
Prostate; 2005 Aug; 64(3):224-39. PubMed ID: 15712212
[TBL] [Abstract][Full Text] [Related]
35. A novel p53 mutant retained functional activity in lung carcinomas.
Ko JL; Chiao MC; Chang SL; Lin P; Lin JC; Sheu GT; Lee H
DNA Repair (Amst); 2002 Sep; 1(9):755-62. PubMed ID: 12509279
[TBL] [Abstract][Full Text] [Related]
36. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets.
Chavez-Reyes A; Parant JM; Amelse LL; de Oca Luna RM; Korsmeyer SJ; Lozano G
Cancer Res; 2003 Dec; 63(24):8664-9. PubMed ID: 14695178
[TBL] [Abstract][Full Text] [Related]
37. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
Zhang Z; Li M; Wang H; Agrawal S; Zhang R
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11636-41. PubMed ID: 13130078
[TBL] [Abstract][Full Text] [Related]
38. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
Grace MJ; Xie L; Musco ML; Cui S; Gurnani M; DiGiacomo R; Chang A; Indelicato S; Syed J; Johnson R; Nielsen LL
Am J Pathol; 1999 Dec; 155(6):1869-78. PubMed ID: 10595917
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a perinecrotic 60 kDa MDM2 isoform within glioma spheroids and glioblastoma biopsy material.
Bell HS; Whittle IR; Bader SA; Wharton SB
Neuropathol Appl Neurobiol; 2005 Apr; 31(2):191-202. PubMed ID: 15771712
[TBL] [Abstract][Full Text] [Related]
40. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
